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Introduction
Juvenile idiopathic arthritis patients refractory to metho-
trexate are eligible for treatment with biologic agents. A
longitudinal sub-analysis (n=53) of the Dutch Arthritis
and Biologicals in Children register previously showed
that disability and health related quality of life (HRQoL)
improved shortly after treatment with etanercept.
Objectives
To investigate long term functional outcome, HRQoL
and treatment changes in the same patients, who started
etanercept >5 years ago.
Methods
Patients were traced and questioned on education and
employment. Data on recent disease status, comorbidities
and structural damage were retrieved. Disability was
assessed by (Child) Health Assessment Questionnaire
((C)HAQ), HRQoL was measured by Child Health
Questionnaire, Short Form 36 and Health Utilities Index
Mark 3. Linear mixed models were used to analyze
changes over time.
Results
43 patients (81% response) started etanercept median
8.5 years (IQR: 7.7-10.3) ago. Median age was 22 years
(IQR: 18-24). 42% had a (C)HAQ of 0.00. HRQoL was
similar to HRQoL shortly after start of etanercept,
except for the domains bodily pain and general health
perception, which deteriorated to levels comparable to
those at start of etanercept. VAS pain also worsened
(median 12 (IQR:2-43)), however pain indicated by VAS
remained lower than at start of etanercept. The unem-
ployment rate (12%) was comparable to the general
population; educational level was higher (77% of patients
>17 years had achieved at least upper secondary educa-
tion). 40% of patients switched to other biologic agents,
40% were still using etanercept and 20% were off anti-
rheumatic treatment. 14% had had joint surgery. There
were no reports of malignancies.
Conclusion
The improvement in HRQoL after start of etanercept
was sustained after 8.5 years. Disability was low. On
many aspects of daily life, patients functioned compar-
ably to or better than the general population. The need
for surgery for 14% of patients stresses the importance
of early treatment of JIA. Chronic pain - also when the
disease is inactive - remains an important issue that
should not be overlooked.
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